Stay Informed

WNDM Medical Inc.

With our number one goal of improving patient outcomes, WNDM Medical Inc., develops, markets and distributes biotechnology products to physicians, hospitals and clinics. We have a strong history of developing long-term, strategic partnerships with a focus on products that fuse nature with science. With a steady focus on innovation and growth, we hold licenses and patents to technologies and processes that ultimately make a positive impact on clinical outcomes for patients.

Our primary products are in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. We project rapid revenue growth based on increasing sales from our FDA-cleared CellerateRX® Surgical Activated Collagen® Adjuvant, as well as anticipated revenues from our FDA-cleared HemaQuell® Resorbable Bone Hemostat.

CORE PRODUCTS

Innovation isn't born. It's bred. That’s why our approach to product development merges science and technology with the goal of creating innovative, safe and cost-effective products for the ever-changing surgery landscape.

Valid in most surgical specialties, our products are cost-effective across the continuum of care. They are supported by our growing internal sales management team and a network of seasoned health care distributors.

 

 

Surgical

logo HemaQuell3

When normal bone healing and fusion are critical, HemaQuell Hemostat provides rapid hemostasis by filling in cut or damaged bone surfaces with a simple, ready-to-use application. And because it is completely resorbed in just 2-7 days, it allows bone to heal normally without interference. Learn more about patient benefits.

Surgical

logo CellerateRX Surgical3

CellerateRX® Surgical is changing collagen’s role in the operating room across specialties where comorbidities and postoperative incisional healing risks are a concern. Find out how CellerateRX® Surgical provides a favorable environment for healing and can help high-risk patients.

 

Investors

WNDM Medical Inc., is an emerging commercial stage company with its primary products in the $11 billion U.S. consumable medical device market and in the $1.5 billion biomaterials market. Our primary focus is the distribution of our unique, patented CellerateRX® Surgical Activated Collagen® Adjuvant, which is FDA-cleared and indicated for all surgical and traumatic wounds, except third degree burns. We have also received FDA-clearance for HemaQuell® Resorbable Bone Hemostat.

WNDM Medical Inc.’s Code of Ethics

Contact Us

Contact Form

 

WNDM Medical Inc.

1200 Summit Avenue
Suite 414
Fort Worth, TX
76102
USA

Phone: 817-529-2300